Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The Impact of PPARβ/ agonism/antagonism on human bone-marrow-derived Mesenchymal Stromal Cells

ABSTRACT: PPARβ/ -ligands are present in the acute respiratory syndrome (ARDS) lung in abundance. Mesenchymal Stromal Cells (MSCs) have shown poor results in ARDS-based clinical trials. In order to determine the potential impact of PPARβ/ agonism/antagonism on human bone-marrow-derived MSCs in vitro, we activated or inhibited the receptor on the cells and/or licensed them with 5ng/ml TNF⍺.

ORGANISM(S): Homo sapiens

PROVIDER: GSE281162 | GEO | 2026/05/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice

Project description:Agonists and antagonists of the glucose-dependent insulinotropic polypeptide receptor (GIPR) enhance body weight loss induced by glucagon-like peptide-1 receptor (GLP-1R) agonism. However, while GIPR agonism decreases body weight and food intake in a GLP-1R-independent manner via GABAergic GIPR+ neurons, it remains unclear whether GIPR antagonism affects energy metabolism via a similar mechanism. Here we show that the body weight and food intake effects of GIPR antagonism are eliminated in mice with global loss of either Gipr or Glp-1r but are preserved in mice with loss of Gipr in either GABAergic neurons of the central nervous system or peripherin-expressing neurons of the peripheral nervous system. Single-nucleus RNA-sequencing shows opposing effects of GIPR agonism and antagonism in the dorsal vagal complex, with antagonism, but not agonism, closely resembling GLP-1R signalling. Additionally, GIPR antagonism and GLP-1R agonism both regulate genes implicated in synaptic plasticity. Collectively, we show that GIPR agonism and antagonism decrease body weight via different mechanisms, with GIPR antagonism, unlike agonism, depending on functional GLP-1R signalling.

2025-03-12 | GSE288514 | GEO

LILRB3 agonism and antagonism using monocolonal antibodies

Project description:LILRB3 agonism and antagonism using monocolonal antibodies

| PRJNA819481 | ENA

Estrogen receptor agonism/antagonism in T47D cells

Project description:Estrogen receptor agonism/antagonism in T47D cells

| PRJNA1055455 | ENA

Effect of PPARβ/δ agonist GW501516 on human and murine mesenchymal stromal cells

Project description:This study employed 3’ RNA-Seq profiling (3RSP) to investigate the transcriptomic effects of the PPARβ/δ agonist GW501516 (1 μM, 24 hours) on mesenchymal stromal cells (MSCs). Treated samples were compared with untreated controls to identify differentially expressed genes. The analysis revealed ANGPTL4 as the most significantly overexpressed gene in the treated condition across multiple experimental models, including murine and human MSCs. Importantly, this upregulation was observed in human MSCs derived from diverse tissues, such as adipose tissue, bone marrow, and umbilical cord, highlighting the consistent response of MSCs to PPARβ/δ activation across species and sources. Further functional experiments demonstrated that ANGPTL4 plays a pivotal role in enhancing the anti-apoptotic properties of MSCs. This effect was evident in both autocrine (self-regulating) and paracrine (targeting other cells) mechanisms, suggesting that ANGPTL4 may act as a key mediator of MSC-based therapeutic effect.

2024-11-29 | GSE283154 | GEO

Transcriptional changes in Wnt antagonism- and TGFβ agonism-induced MSC chondrogenesis.

Project description:Transcriptional changes in Wnt antagonism- and TGFβ agonism-induced MSC chondrogenesis.

| PRJNA870902 | ENA

GLP-1 directed NMDA receptor antagonism for obesity treatment

Project description:The N-methyl-D-aspartate (NMDA) receptor is a glutamate-activated cation channel critical to many processes in the brain. Genome-wide association studies (GWAS) suggest that glutamatergic neurotransmission and NMDA receptor-mediated synaptic plasticity is important for body weight homeostasis1. Here, we report the engineering and preclinical development of a first-in-class bimodal molecule that integrates NMDA receptor antagonism with glucagon-like peptide-1 (GLP-1) receptor agonism to effectively reverse obesity, hyperglycemia, and dyslipidemia in rodent models of metabolic disease. We demonstrate that GLP-1-directed delivery of the NMDA receptor antagonist MK-801 affects NMDA receptor-mediated synaptic plasticity in the hypothalamus. Importantly, peptide-targeting of MK-801 specifically to GLP-1 receptor-expressing brain regions circumvent adverse physiological and behavioral effects associated with MK-801 monotherapy. In sum, our approach demonstrates the feasibility of cell specific ionotropic receptor-modulation via peptide targeting and highlights the therapeutic potential of unimolecular mixed GLP-1 receptor agonism and NMDA receptor antagonism for obesity treatment.

2024-04-26 | PXD045816 | Pride

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.

Project description:Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.

| PRJNA317919 | ENA

Gene expression by AR agonism and AR antagonism in isotope-labeled PCa cells

Project description:Gene expression by AR agonism and AR antagonism in isotope-labeled PCa cells

| PRJNA1173867 | ENA

Genome-wide maps of H3K27ac, PPARβ/δ and Pol II localization in HUVECs

Project description:H3K27Ac is one of the expressed enhancer markers, PPARβ/δ is a transcription factor and Pol II (RNA polymerase II) is an enzyme which catalyzes the transcription of DNA to synthesize precursors of mRNA and most snRNA and microRNA. These genomic localization in endothelial cells is unknown in endothelial cells. This time, we established a new antibody for H3K27ac, PPARβ/δ and Pol II and performed ChIP-seq to identify H3K27ac, PPARβ/δ and Pol II binding site in whole genome manner under PPARβ/δ agonist and/or hypoxia. We used chromatin immunoprecipitation with deep sequencing (ChIP-seq) of HUVECs treated with PPARβ/δ agonist (GW501516 100nM) and/or hypoxia (1%O2) for 24hours, then H3K27ac, PPARβ/δ and Pol II binding regions were identified. Normoxia and DMSO was used as a control condition. HUVECs were used within the first 6 passages.

2014-03-06 | E-GEOD-50144 | biostudies-arrayexpress

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. [ChIP-seq]

Project description:Transcriptomic changes and estrogen and progesterone receptor binding in multiple ER+/PR+ models (eight ER+/PR+ patient tumors, various T47Ds, ZR75) and multiple ER+/PR-negative models (four ER+/PR- patient tuumors, PR-deficient T47D and MCF7 cells) treated with various hormone combinations. Results: In isolation, estrogen and progestin act as genomic agonists by regulating the expression of common target genes in similar directions, but at different levels. Similarly, in isolation, progestin is also a weak phenotypic agonist of estrogen action. However, in the presence of both hormones, progestin behaves as a phenotypic estrogen antagonist. PR remodels nucleosomes to noncompetitively redirect ER genomic binding to distal enhancers enriched for BRCA1 binding motifs and sites that link PR and ER/PR complexes. Importantly, when both hormones are present, progestin modulates estrogen action such that responsive transcriptomes, cellular processes and ER/PR recruitment to genomic sites correlate with those observed with PR alone, but not ER alone. Conclusions: Genomic Agonism and Phenotypic Antagonism between Estrogen and Progesterone Receptors in Breast Cancer. Individual and concerted actions of ER and PR highlight the prognostic and therapeutic value of PR in ER+/PR+ breast cancers. ER+/PR+ and ER+/PR-deficient model systems were deprived of steroids by culturing them in phenol red free RPMI 1640 media that is supplemented with 10% charcoal-stripped fetal bovine serum and 1% penicillin/streptomycin. Subsequently, these steroid-deprived models were treated with either vehicle, 10 nM estradiol, 10 nM progestin R5020 or 10 nM of both the hormones and genomics (ChIP-seq and RNA-seq) was performed. ChIP-seq was done after 45 minutes of hormone treatments. For cell models, RNA-seq was done after 12 hours of hormone treatments. Tumor explants were treated with either 24 or 48 hours.

2016-06-01 | E-GEOD-80367 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data